Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 3/20 | 0.39 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446130 | 1.00 | TNF (0.46) | TNFLMNAALOX15KDM4EDHFR | |
| SCHEMBL7976084 | 0.85 | LMNA (0.44) | LMNAALOX15KDM4EDHFRSLC19A1 | |
| SCHEMBL7257431 | 0.83 | THRB (0.46) | ALOX15THRBMAPTSMN1; SMN2 | |
| SCHEMBL9087773 | 0.83 | NR1H2 (0.39) | TNFLMNAALOX15KDM4EDHFR | |
| SCHEMBL7986178 | 0.80 | TNF (0.47) | TNFALOX15KDM4EMAPTNPC1 | |
| SCHEMBL7900182 | 0.79 | THRB (0.44) | LMNAALOX15THRBMAPTSMN1; SMN2 | |
| SCHEMBL23877050 | 0.79 | NR1H2 (0.39) | LMNAALOX15KDM4EDHFRSLC19A1 | |
| SCHEMBL3797261 | 0.78 | TNF (0.58) | TNFLMNAALOX15KDM4EMAPT | |
| SCHEMBL6447529 | 0.78 | DHFR (0.52) | ALOX15KDM4EDHFRSLC19A1MAPT | |
| SCHEMBL6447536 | 0.78 | DHFR (0.52) | ALOX15KDM4EDHFRSLC19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855712-B2 | Combination of benzoquinazoline antifolates and protecting agents | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-6762188-B1 | INHIBITING THYMIDYLATE SYNTHASE; COLON, BREAST OR LUNG CARCINOMA | SMITHKLINE BEECHAM CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1199307-B1 | Pharmaceutically active benzoquinazoline compounds | WELLCOME FOUND (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203924-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SMITH GARY KEITH (US) | 2003-10-30 | — | — | US | disclosed |
| US-6579877-B2 | Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents | SMITHKLINE BEECHAM CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020137748-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SMITH GARY KEITH (US) | 2002-09-26 | — | — | US | disclosed |
| EP-0535034-B1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | WELLCOME FOUND (GB) | 2002-08-14 | — | — | EP | disclosed |
| EP-1199307-A1 | Pharmaceutically active benzoquinazoline compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-04-24 | — | — | EP | disclosed |
| US-6358952-B1 | SIDE EFFECT REDUCTION WHEN ADMINISTERING NON-COMPETITIVE THYMIDYLATE SYNTHASE INHIBITOR AS ANTITUMOR AGENT | SMITHKLINE BEECHAM CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6306865-B1 | SYNTHASE INHIBITORS AND ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| US-6090941-A | Pharmaceutically active benzoquinazoline compounds | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0675719-B1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | WELLCOME FOUND (GB) | 1998-06-10 | — | — | EP | disclosed |
| US-5663337-A | ENZYME, ANTITUMOR | GLAXO WELLCOME INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5661155-A | THYMIDYLATE SYNTHASE INHIBITOR; ADMINISTERING TO THE MAMMAL SUFFERING FROM LEUKEMIA OR TUMOR 2-(5-(((1,2-DIHYDRO-3-METHYL-1-OXOBENZO(F)QUINAZOLINE-9-YL) METHYL)AMINO)-1-OXO-2-ISOINDOLINYL)GLUTARIC ACID OR SALTS | GLAXO WELLCOME INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5405851-A | Administering benzoquinazoline thymidylate synthase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1994014448-A1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
| WO-1991019700-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203924-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SLC19A1, DHFR, FOLR2 | TNF 3025/4885LMNA 3704/4885ALOX15 1823/4885 |
| US-20020137748-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SLC19A1, DHFR, FOLR2 | TNF 3025/4885LMNA 3704/4885ALOX15 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.